Deutsche Raises Valeant Price Target On Extended Xifaxan Exclusivity

The stay in the Xifaxan litigation between Valeant Pharmaceuticals and Teva was recently extended to July 30, 2018, from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note.